Hemostasis and Thrombosis Laboratory, Departments of Medicine and Biochemistry, Molecular Oncology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.
EMBO Mol Med. 2011 Jul;3(7):370-84. doi: 10.1002/emmm.201100145. Epub 2011 May 18.
Sepsis is a deadly disease characterized by the inability to regulate the inflammatory-coagulation response in which the endothelium plays a key role. The cause of this perturbation remains poorly understood and has hampered the development of effective therapeutics. Matrix metalloproteases (MMPs) are involved in the host response to pathogens, but can also cause uncontrolled tissue damage and contribute to mortality. We found that human sepsis patients had markedly elevated plasma proMMP-1 and active MMP-1 levels, which correlated with death at 7 and 28 days after diagnosis. Likewise, septic mice had increased plasma levels of the MMP-1 ortholog, MMP-1a. We identified mouse MMP-1a as an agonist of protease-activated receptor-1 (PAR1) on endothelial cells. MMP-1a was released from endothelial cells in septic mice. Blockade of MMP-1 activity suppressed endothelial barrier disruption, disseminated intravascular coagulation (DIC), lung vascular permeability as well as the cytokine storm and improved survival, which was lost in PAR1-deficient mice. Infusion of human MMP-1 increased lung vascular permeability in normal wild-type mice but not in PAR1-deficient mice. These findings implicate MMP-1 as an important activator of PAR1 in sepsis and suggest that therapeutics that target MMP1-PAR1 may prove beneficial in the treatment of sepsis.
脓毒症是一种致命疾病,其特征是无法调节炎症-凝血反应,内皮在其中起着关键作用。这种紊乱的原因仍不清楚,这阻碍了有效的治疗方法的发展。基质金属蛋白酶(MMPs)参与宿主对病原体的反应,但也会导致不受控制的组织损伤,并导致死亡率增加。我们发现,人类脓毒症患者的血浆前 MMP-1 和活性 MMP-1 水平明显升高,这与诊断后 7 天和 28 天的死亡相关。同样,脓毒症小鼠的 MMP-1 同源物 MMP-1a 血浆水平也升高。我们确定了小鼠 MMP-1a 是内皮细胞上蛋白酶激活受体-1(PAR1)的激动剂。MMP-1a 从脓毒症小鼠的内皮细胞中释放出来。抑制 MMP-1 活性可抑制内皮屏障破坏、弥散性血管内凝血(DIC)、肺血管通透性以及细胞因子风暴,并提高存活率,而 PAR1 缺陷型小鼠则失去了这种作用。人 MMP-1 的输注增加了正常野生型小鼠的肺血管通透性,但在 PAR1 缺陷型小鼠中则没有。这些发现表明 MMP-1 是脓毒症中 PAR1 的重要激活剂,并表明靶向 MMP1-PAR1 的治疗方法可能对脓毒症的治疗有益。